Vivoryon Therapeutics NV Q4 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Christopher Ross Redhead - goetzpartners securities Limited, Research Division - Analyst : Yes. Just a quick comment on the trial in terms of what's going on with the other guys and in the space. Lilly, for instance, they've sort of slowed their development in the sense of having to go into a full Phase III. So they sort of abandoned the accelerated development. So in principle, you could leapfrog those products or at least your program could -- you could get an approval at the same time or even before they do. Is that the case?

Question: Christopher Ross Redhead - goetzpartners securities Limited, Research Division - Analyst : Yes. But basically, you -- potentially you could have caught up in a way that you wouldn't maybe have anticipated before they made that decision to not go through accelerated approval, right? So it's a -- it is -- it must be an advantage for you guys that they've accelerated to the Phase III.

Question: Christopher Ross Redhead - goetzpartners securities Limited, Research Division - Analyst : Yes. So you basically get -- your time line for approval is much more similar potentially than it was. And equally, the data that you've got already with the antibody -- the studies that you've been doing suggest that the trial -- even though the other products may be around, that you can use them in conjunction, in combination with those products and make them more safe potentially by reducing the dose? Is that -- that's case, isn't it?

Question: Christopher Ross Redhead - goetzpartners securities Limited, Research Division - Analyst : No, no, I appreciate that. The other -- yes, just a quick -- another question to clarify on the licensing of the other programs, the non-AD programs. Do you see any prospects of licensing deals on those? Or are you not going to be drawn on that?